Torthaí cuardaigh - Norbert Gattermann

Beachtaigh na torthaí
  1. 1
    Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload

    Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload de réir Norbert Gattermann

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    The Treatment of Secondary Hemochromatosis

    The Treatment of Secondary Hemochromatosis de réir Norbert Gattermann

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Iron overload in myelodysplastic syndromes (MDS)

    Iron overload in myelodysplastic syndromes (MDS) de réir Norbert Gattermann

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Valproic acid for the treatment of myeloid malignancies

    Valproic acid for the treatment of myeloid malignancies de réir Andrea Kuendgen, Norbert Gattermann

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Iron overload in MDS—pathophysiology, diagnosis, and complications

    Iron overload in MDS—pathophysiology, diagnosis, and complications de réir Norbert Gattermann, Eliezer A. Rachmilewitz

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Myelodysplastic Syndromes

    Myelodysplastic Syndromes de réir Peter L. Greenberg, Neal S. Young, Norbert Gattermann

    Foilsithe / Cruthaithe 2002
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Myelodysplastic Syndromes

    Myelodysplastic Syndromes de réir Ulrich Germing, Guido Kobbe, Rainer Haas, Norbert Gattermann

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    The evaluation of iron deficiency and iron overload

    The evaluation of iron deficiency and iron overload de réir Norbert Gattermann, Martina U. Muckenthaler, Andreas E. Kulozik, Georgia Metzgeroth, Jan Hastka

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Myelodysplastic Syndromes in Patients Younger Than Age 50

    Myelodysplastic Syndromes in Patients Younger Than Age 50 de réir Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Barbara Hildebrandt, Rainer Haas, Norbert Gattermann, Ulrich Germing

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Heteroplasmic Point Mutations of Mitochondrial DNA Affecting Subunit I of Cytochrome c Oxidase in Two Patients With Acquired Idiopathic Sideroblastic Anemia

    Heteroplasmic Point Mutations of Mitochondrial DNA Affecting Subunit I of Cytochrome c Oxidase in Two Patients With Acquired Idiopathic Sideroblastic Anemia de réir Norbert Gattermann, Stefan Retzlaff, Yanling Wang, Götz Hofhaus, Jürgen J. Heinisch, Carlo Aul, Wolfgang Schneider

    Foilsithe / Cruthaithe 1997
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable

    High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifia... de réir Norbert Gattermann, Johan Billiet, Ralf Kronenwett, E. Zipperer, Ulrich Germing, Friedel Nollet, A. Criel, Dominik Selleslag

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Carta
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

    Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid de réir Andrea Kuendgen, Corinna Strupp, Manuel Aivado, A. Bernhardt, Barbara Hildebrandt, Rainer Haas, Ulrich Germing, Norbert Gattermann

    Foilsithe / Cruthaithe 2004
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

    The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome de réir E. Zipperer, D. Pelz, Kathrin Nachtkamp, A. Kuendgen, C. Strupp, Norbert Gattermann, Rainer Haas, Ulrich Germing

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes

    Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes de réir Sabine Knipp, Barbara Hildebrand, Andrea Kündgen, Aristoteles Giagounidis, Guido Kobbe, Rainer Haas, Carlo Aul, Norbert Gattermann, Ulrich Germing

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

    Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes de réir Judith Neukirchen, Sabine Blum, Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Rainer Haas, Carlo Aul, Norbert Gattermann, Ulrich Germing

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Chronic myelomonocytic leukemia in the light of the WHO proposals

    Chronic myelomonocytic leukemia in the light of the WHO proposals de réir Ulrich Germing, C. Strupp, S. Knipp, A. Kuendgen, Aristoteles Giagounidis, B. Hildebrandt, C. Aul, R Haas, Norbert Gattermann, John M. Bennett

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia

    The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia de réir Andrea Kuendgen, Mathias Schmid, Richard F. Schlenk, Sabine Knipp, Barbara Hildebrandt, Christian Steidl, Ulrich Germing, Rainer Haas, Hartmut Döhner, Norbert Gattermann

    Foilsithe / Cruthaithe 2005
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes

    Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes de réir Lewis R. Silverman, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Eva Hellström‐Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore, John F. Seymour

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34+ hematopoietic stem cells

    Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow–derived and circulating human CD34+ hematopoietic stem cells de réir Ulrich Steidl, Ralf Kronenwett, Ulrich‐Peter Rohr, Roland Fenk, Slawomir Kliszewski, Christian Maercker, Peter Neubert, Manuel Aivado, J. H. Koch, Olga Modlich, Hans Bojar, Norbert Gattermann, Rainer Haas

    Foilsithe / Cruthaithe 2002
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

    High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients de réir Jeffrey W. Tyner, Heidi S. Erickson, Michael W. Deininger, Stephanie G. Willis, Christopher A. Eide, Ross L. Levine, Michael C. Heinrich, Norbert Gattermann, D. Gary Gilliland, Brian J. Druker, Marc Loriaux

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: